Delivery Order SPE2DR25D2216-SPE2DR26F7UL6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,774.43 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count packages) on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical procurement executed under a non-set-aside designation. The award is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $2,691.55 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count) with a firm fixed price contract type and an ultimate completion date of September 16, 2025. This non-set-aside, competitively awarded delivery order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with...
- The Defense Logistics Agency awarded a $2,275.28 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count) with an ultimate completion date of June 3, 2025. This non-set-aside, competitively awarded contract reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement needs, particularly for military and veteran healthcare systems. The delivery order will be performed at the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,863.01 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count package). This is a firm fixed price, non-set-aside contract with an ultimate completion date of November 28, 2025, and was awarded on November 26, 2025. The pharmaceutical product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $15,850.71 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count units) on a firm fixed price basis. The order, with a completion deadline of November 6, 2025, represents a non-competitive set-aside delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Entecavir 0.5 mg tablets (30-count) valued at $3,383.40 under a firm fixed-price contract. The award, issued on September 22, 2025, with an ultimate completion date of September 23, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $23,536.24 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count units) under a firm fixed-price contract structure. The award, issued on December 1, 2025, with an ultimate completion date of December 2, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its...
- The Defense Logistics Agency awarded a $1,996.61 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Entecavir 0.5 mg tablets (30-count units). This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, consistent with AmerisourceBergen's typical federal procurement profile....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of Entecavir 0.5 mg tablets (30-count) with a contract value of $1,267.02 and an ultimate completion date of December 12, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing indefinite delivery contract vehicle. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Entecavir 0.5 mg tablets (30-count) valued at $2,795.02, with completion scheduled for November 13, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement. The performance location is the company's corporate office in Conshohocken,...
- SPE2DR25D2216Indefinite Delivery Contract
- SPE2DR25D2216-SPE2DR26F7UL6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,389.37 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count package), with a completion date of December 12, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply needs, likely destined for military or veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running through December 2026 that provides comprehensive global pharmaceutical support. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, with an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies distributed across multiple therapeutic domains. The company's demonstrated capability to fulfill federal requirements through open competition, combined with its substantial IDC framework with DLA, enables efficient delivery of essential pharmaceutical products to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 12/10/25 |